Pharmaceuticals

The biotech firm lands a major private placement, extending its cash runway to 2028 and signaling strong investor confidence in its novel drug platform.

With blockbuster preliminary sales and rapid patient adoption, Liquidia's new inhaled therapy is challenging established players in the lung disease space.

A new AI-designed vaccine, TG4050, has prevented relapse in all head and neck cancer patients in a key trial, signaling a breakthrough in personalized medicine.

A major pharma giant is betting on artificial intelligence to accelerate cancer drug discovery, a move that could reshape the future of oncology treatment.

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

As Valneva meets investors, all eyes are on its pivotal Lyme disease vaccine data, a potential game-changer for public health and the company's future.

Ventyx Biosciences is under investigation for misleading investors after a trial delay caused a 15% stock drop, even as a pharma giant moves to acquire it.

A legal battle over the blockbuster cancer drug Jemperli escalates, with billions in future royalties and a company's strategic future on the line.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

As healthcare costs surge, WTW names Sheila Nordquist its new North America H&B leader. Her mandate: drive growth and navigate an evolving benefits landscape.

Backed by Pfizer Ventures, Enodia Therapeutics' novel AI platform aims to stop diseases by degrading proteins at their source, a major shift in drug discovery.

Paris-based Enodia Therapeutics lands €20.7M to advance its AI platform that degrades disease-causing proteins at the point of synthesis, targeting new cures.

New research reveals a stark disconnect between clinical views and patient reality in atopic dermatitis, with millions suffering severe, overlooked impacts.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

Global consulting giant Andersen partners with niche firm Scimitar to tackle pharma's biggest challenges, signaling a new model for expertise at scale.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

A new study on oral testosterone therapy for men 65-80 could reshape geriatric care, challenge FDA guidelines, and unlock a multi-billion dollar market.

With pivotal data for its sickle cell drug and a new myelofibrosis program, Cellarity's AI-driven 'Cell State-Correcting' platform faces a crucial test.

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.